Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lantheus Holdings, Inc.

< Previous 1 2 3 Next >
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the Jefferies Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports First Quarter 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Two Key Executive Promotions
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH PNT
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Reports Third Quarter 2022 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
From Lantheus Holdings, Inc.
Via GlobeNewswire
Tickers LNTH
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
From Lantheus Holdings, Inc.
Via Business Wire
Tickers LNTH
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.